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ABSTRACT
Identification of mutations in the gene encoding the serine/threonine-protein 
kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase 
(MAPK) pathway in around 50% of malignant melanomas have led to the development 
and regulatory approval of targeted pathway inhibitor drugs. A proportion of 
patients are intrinsically resistant to BRAF inhibitors, and most patients who initially 
respond, acquire resistance within months. In this review, we discuss pathway 
inhibitors and their mechanisms of resistance, and we focus on numerous efforts to 
improve clinical benefits through combining agents with disparate modes of action, 
including combinations with checkpoint inhibitor antibodies. We discuss the merits 
of combination strategies based on enhancing immune responses or overcoming 
tumor-associated immune escape mechanisms. Emerging insights into mechanisms of 
action, resistance pathways and their impact on host-tumor relationships will inform 
the design of optimal combinations therapies to improve outcomes for patients who 
currently do not benefit from recent treatment breakthroughs.
BRAF INHIBITORS AND RESISTANCE 
MECHANISMS IN PATIENTS WITH 
MELANOMA
Malignant melanoma is the fifth most common 
malignancy in the UK, making up 4% of all cancer 
diagnoses, with only 20% of people diagnosed with 
metastatic disease surviving beyond five years [1, 2]. 
The clinical management of patients with unresectable 
or metastatic melanoma has been transformed in 
recent years with the emergence of novel targeted and 
immunomodulatory therapeutics, including checkpoint 
blockade antibodies designed to trigger T cell activation 
and promote anti- tumor immune responses (Table 1). 
Prior to this, dacarbazine chemotherapy or combination 
regimens, in some cases with IL-2 or IFNα2b 
immunotherapy, were the only approved treatments, 
demonstrating short median overall survival benefits of 
less than 9 months [3].
Approximately 50% of melanomas carry mutations 
in the gene encoding BRAF, part of the MAPK pathway 
involved in regulating cell growth and proliferation 
(Figure 1A) [4]. This pathway involves a signaling cascade 
initiated by the binding of growth factors or cytokines to 
their respective receptors, resulting in activation of Ras, 
which then recruits Raf proteins, a family of protein kinases 
including BRAF, to the cell membrane [5]. Phosphorylation 
of Raf allows the activation of MEK1 (MAP kinase/ERK 
kinase 1), which positively regulates the extracellular 
signal-regulated kinases (ERK). ERK can then directly 
phosphorylate downstream transcription factors, leading to 
increased transcription and eventual cell growth [5].
                                                                             Review
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Table 1: U.S. FDA-approved agents and combinations for the treatment of malignant melanoma
Agent/
Combination
(brand names) 
Year of first 
regulatory 
approval
Specificity Class Mechanisms of action Indication
Chemotherapies
Dacarbazine
(DTIC-Dome®) 
1975 Non-specific Alkylating agent Interferes with cancer cells leading to DNA 
damage, cell cycle arrest and tumor cell apoptosis
Stage IV melanoma
Immunotherapies
IFNα2b 
(INTRON® A) 
1995 IFNα Receptor 1 and 2 Cytokine Multifunctioning immunoactivatory cytokine 
enhances anti-tumoral immune response, anti-
angiogenic, anti-proliferative and pro-apoptotic 
properties 
Adjuvant setting after surgery to 
Stage III patients free of disease, at 
high risk recurrence, or
Stage IIB or Stage IIC patients 
with lesions of > 4 mm Breslow 
thickness)
High dose IL-2 
(Aldesleukin, 
Proleukin®) 
1998 IL-2 receptor expressed 
on lymphocytes 
Cytokine Immune activating, increases activation and 
proliferation of immune cells (e.g. T, NK, B cells) 
Advanced metastatic melanoma
Pegylated IFNα2b 
(Sylatron®)
2011 IFNα receptor 1 and 2 Cytokine Modified (pegylated) form of IFNα2b with 
increased half-life and enhanced therapeutic 
efficacy
Microscopic or macroscopic nodal 
melanoma following surgical 
resection, including therapeutic 
lymph node dissection
Ipilimumab 
(Yervoy®) 
2011 CTLA-4 expressed on 
T cells 
Humanized 
monoclonal 
antibody (mAb) 
Inhibition of checkpoint receptor CTLA-4 
preventing engagement with CD80/CD86, activates 
immune system enhancing T cell activation and 
targeting CTLA-4-expressing Tregs
Stage III or Stage IV melanoma
Pembrolizumab 
(KEYTRUDA®) 
2014 PD1 expressed on T 
cells 
Humanized 
monoclonal 
antibody (mAb)
Inhibition of checkpoint receptor PD-1, prevents 
interaction between PD-1 and its ligands PD-L1 
and PD-L2, releasing PD-1 pathway-mediated 
inhibition, prevents T cell anergy or deletion, 
activates immune system enhancing T cell 
activation
Unresectable Stage III melanoma or 
Stage IV melanoma
Nivolumab 
(OPDIVO®)
2014 PD1 expressed on T 
cells
Humanized 
monoclonal 
antibody (mAb)
Targets the inhibitory receptor PD-1 prevents 
interaction between PD-1 and its ligands PD-L1 
and PD-L2, releasing PD-1 pathway-mediated 
inhibition, prevents T cell anergy or deletion, 
activates immune system enhancing T cell 
activation
Unresectable Stage III melanoma or 
Stage IV melanoma
Talimogene 
laharparepvec 
(IMLYGIC® or 
T-Vec)
2015 Modified oncolytic 
herpes virus 
Targeted 
Oncolytic virus 
immunotherapy
Virus construct designed to replicate within cancer 
cells and produce granulocyte-macrophage colony-
stimulating factor (GM-CSF) causing cell lysis and 
death, and releasing tumor-associated antigens. 
Alongside GM-CSF, this may promote an anti-
tumor immune response
Local treatment of unresectable 
cutaneous, subcutaneous, and nodal 
lesions in patients with recurrent 
melanoma after surgery
Ipilimumab 
(Yervoy®)  
&
Nivolumab 
(OPDIVO®)
(Combination)
2015 CTLA-4 expressed on 
T cells
&
PD1 expressed on T 
cells
Immune checkpoint inhibitors that target separate, 
distinct checkpoint pathways. Inhibition of these 
immune checkpoint pathways results in enhanced 
T cell function greater than the effects of either 
antibody alone
Unresectable Stage III melanoma or 
Stage IV melanoma
Targeted therapies of BRAF/MEK
Verumafenib 
(Zelboraf®) 
2011 BRAF V600E, mutated 
form of BRAF protein 
Small molecule 
kinase inhibitor 
Blocks activity of the V600E-mutated form of 
BRAF, and thus the mitogen-activated protein 
kinase pathway, reducing proliferation of 
melanoma cells carrying the mutation 
Unresectable Stage III melanoma or 
Stage IV melanoma that carry the
BRAF V600E mutation
Dabrafenib
(Tafinlar*)
2013 BRAF V600E mutated 
form of BRAF protein
Small molecule 
kinase inhibitor
Blocks mitogen-activated protein kinase pathway 
reducing proliferation of melanoma cells carrying 
mutation
Unresectable Stage III melanoma or 
Stage IV melanoma that carry the
BRAF V600E mutation
Trametinib 
(Mekinist*)
2013 Mitogen-activated 
extracellular signal 
regulated kinase 1 
(MEK1) and MEK2 
Small molecule 
kinase inhibitor
Selective, allosteric inhibitor of mitogen-activated 
extracellular signal regulated kinase 1 (MEK1) 
and MEK2 activation and kinase activity. This 
extracellular signal related kinase (ERK) pathway 
is often activated by mutated forms of BRAF in 
melanoma and other cancers. Blocks mitogen-
activated protein kinase pathway reducing 
proliferation of melanoma cells carrying mutation.
Unresectable Stage III melanoma or 
Stage IV melanoma that carry the
BRAF V600E mutation
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The V600E missense valine to glutamic acid 
mutation accounts for approximately 80–90% of 
BRAF mutations [4, 6–7]. This mutation leads to a 
conformational change, resulting in constitutive activation 
of BRAF, and consequently of the MAPK/ERK pathway, 
promoting survival and proliferation of melanoma cells. 
Other BRAF mutations include V600K, V600R and 
V600M, estimated as being present in 7.8%, 1% and < 
1% of melanomas, respectively [8, 9–10]. Other gene 
mutations in melanoma include NRAS, GNAQ and KIT, 
estimated to be present in 13–25%, 1.3% (but much more 
in uveal melanoma) and 2–8% (but more in acral/mucosal 
subtypes) of melanomas respectively [11, 12–13]. 
Following the discovery of the V600E mutation, 
targeted therapies such as the mutant BRAF-specific 
small molecule inhibitors vemurafenib and dabrafenib, 
were developed. Vemurafenib was the first targeted drug 
to show a survival benefit in metastatic melanoma, in 
the context of a phase III trial. In the phase III BRIM3 
registration trial in 2011, vemurafenib was compared 
with dacarbazine for the first line treatment of BRAFV600E 
mutant metastatic melanoma. The objective response 
rate (ORR) for vemurafenib was 48% (95% Confidence 
Interval [CI] 42–55) compared to 5% (95% CI, 3–9) for 
dacarbazine (P < 0.001), and the median progression-free 
survival (PFS) was 5.3 months vs. 1.6 months, respectively 
(Hazard Ratio [HR] 0.26; 95% CI 0.20–0.33) [14]. The 
relative risk reduction for death or disease progression was 
74%, for vemurafenib compared to dacarbazine [14].
Another selective BRAF inhibitor, dabrafenib, 
was subsequently developed and showed similar clinical 
benefits. In the phase III trial of first line dabrafenib vs. 
dacarbazine in mutation-positive metastatic melanoma, 
median PFS was 5.1 months for dabrafenib, vs. 2.7 months 
for dacarbazine (HR 0.30; 95% CI 0.18–0.51; P < 0.0001). 
In addition, ORR was 50% vs. 3% [15]. 
Following on from the success of BRAF inhibitors, 
MEK inhibitors were subsequently developed. The 
first of these, trametinib, demonstrated an ORR of 
22% vs. 8% for dacarbazine, and a median PFS of 4.8 
months vs. 1.5 months (HR 0.45; 95% CI, 0.33–0.63; 
P < 0.001) in BRAF-mutant metastatic melanoma in the 
phase III METRIC trial [16]. Furthermore, cobimetinib, 
a selective MEK1/2 inhibitor, has been shown to act on 
non-phosphorylated as well as phosphorylated MEK and 
can reduce ERK activation. Cobimetinib was safe and 
demonstrated some partial responses in a Phase I trial 
[17]. Further development was undertaken in combination 
trials. 
In addition to treating disseminated metastatic 
disease, BRAF/MEK inhibitors may also provide an 
effective neoadjuvant strategy for local or regional 
BRAFV600E mutant melanoma, allowing surgical removal of 
previously inoperable melanomas [18]. Kolar et al. report 
the use of neoadjuvant vemurafenib in a patient with an 
initially inoperable solitary melanoma brain metastasis. 
Vemurafenib treatment caused substantial tumor 
shrinkage, allowing subsequent complete resection of the 
metastasis [19]. Similarly, vemurafenib therapy induced 
tumor regression in a patient with unresectable lymph 
node metastases, after which the patient became eligible 
for radical surgery [20]. Furthermore, dual BRAF/MEK 
inhibition (dabrafenib and trametinib) was successfully 
employed as neoadjuvant treatment for advanced ‘in 
transit’ melanoma [21]. However, prospective studies are 
required to determine whether neoadjuvant BRAF/MEK 
inhibitor therapy will have an impact on patient survival.
Despite improvements in progression-free survival, 
most patients with BRAF-mutant metastatic melanoma 
still demonstrated disease progression within months 
following treatment with BRAF or MEK inhibitor 
monotherapy due to development of resistance [22]. 
Subsequently, research aimed at understanding the ways 
by which tumors become resistant to BRAFV600E-targeted 
therapy has prompted the use of multiple drugs in concert 
to attempt to maximize survival.
Intrinsic resistance to BRAF inhibitors
Early trials indicated that around 20% of patients 
with BRAFV600E mutant melanomas did not respond to 
BRAF inhibitors [23]. Such patients were described as 
having intrinsic resistance to BRAF inhibition. Malignant 
melanomas are extremely heterogeneous, and tumors 
acquire new mutations as they move from primary lesions 
to metastases [24]. As a result, while some melanoma 
Dabrafenib
(Tafinlar*)
&
Trametinib 
(Mekinist*) 
(Combination)
2014 BRAF V600E mutated 
form of BRAF protein
&
Mitogen-activated 
extracellular signal 
regulated kinase 1 
(MEK1) and MEK2
Small molecule 
kinase inhibitors
Simultaneous inhibition of mutant BRAF 
(dabrafenib) and MEK kinases (trametinib)
Unresectable Stage III melanoma or 
Stage IV melanoma that carry the
BRAF V600E mutation
Verumafenib 
(Zelboraf®) 
&
Cobimetinib 
(COTELLIC)
(Combination)
2015 BRAF V600E mutated 
form of BRAF protein
&
Mitogen-activated 
extracellular signal 
regulated kinase 1 
(MEK1) and MEK2
Small molecule 
kinase inhibitors
Simultaneous inhibition of mutant BRAF 
(dabrafenib) and MEK kinases (cobimetinib)
Unresectable Stage III melanoma or 
Stage IV melanoma that carry the
BRAF V600E mutation
mAb: monoclonal antibody; IFN: interferon; IL: interleukin.
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cells may carry the V600E BRAF mutation, others, 
within the same patient, may carry different mutations 
not susceptible to BRAF inhibition. Major mechanisms of 
intrinsic resistance include (Table 2).
Loss of PTEN
One of the most common mutations leading to 
intrinsic BRAF resistance is loss of the phosphatase and 
tensin homolog (PTEN) gene, which occurs in up to 35% 
of melanomas [25]. PTEN is a tumor suppressor and a 
crucial negative regulator of Phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) [26]. Therefore, decreased 
responses to BRAF inhibition seen in patients with 
concurrent BRAF activation and PTEN loss, is thought to 
be due to constitutive activation of the PI3K/AKT (Protein 
kinase B) pathway (Figure 1A). Increased activation of 
this pathway leads to cellular proliferation, growth and 
survival [27].
RAC1P29S mutations
RAC1 regulates cellular motility and proliferation, 
and is a GTPase effector of RAS. It has been suggested 
that the RAC1P29S somatic mutation might confer BRAF 
resistance by sustaining MAPK signaling in the presence 
of BRAF inhibitors. Indeed a study by Watson et al found 
that a RAC1P29S mutation in melanoma cell lines led to 
resistance to BRAF inhibition in vitro and in vivo [28]. 
This was confirmed in the patient setting by Van Allen et 
al. who found that more than a fifth of melanoma patients 
exhibiting intrinsic BRAF resistance, expressed mutations 
in RAC1 [29]. 
Loss of NF1 tumor suppressor gene
NF1 is a negative regulator of RAS, the first 
signaling protein in the MAPK pathway. Loss of NF1 via 
mutation means negative inhibition of RAS stops, and 
RAS levels increase. This activates the protein kinase 
CRAF and leads to activation of the MAPK pathway [30], 
even in the presence of BRAF inhibition.
Amplification of CCND1
CCND1 encodes Cyclin D1, a key protein in the 
regulation of the cell cycle. Cell lines with basal levels 
of Cyclin D1 have been reported to be less dependent on 
the BRAF signaling pathway [31]. Therefore, in cells with 
amplified CCND1 where more Cyclin D1 is produced, 
administration of BRAF inhibitors does not stop cells 
from proliferating, as they do not require BRAF in order 
to grow.
MAP3K8 overexpression
Overexpression of MAP3K8, a gene that encodes 
the COT protein, has also been associated with resistance 
to BRAF inhibitors. A study noted that depleting V600E 
BRAF levels in cells correlated with increased levels of 
COT [32]. Notably, COT could independently activate the 
MAPK/ERK pathway [32]. Thus, patients with intrinsic 
overexpression of this protein, who are exposed to 
BRAF inhibitors, respond by producing further excessive 
amounts of COT and, rather than slowing cellular 
proliferation, the tumor burden increases.
Hepatocyte growth factor (HGF) secretion by stromal 
cells
Secretion of HGF by stromal cells leads to 
activation of MET, a receptor for HGF. Binding of HGF 
to MET could reactivate the MAPK/ERK and PI3K/AKT 
pathways and therefore lead resistance to BRAF inhibition 
[33]. The identification of this mechanism was interesting 
as it demonstrated that the microenvironment of the tumor 
could influence its resistance to therapy.
Acquired resistance to BRAF inhibitors
Patients who initially respond to BRAF inhibitor 
treatment, most often eventually acquire resistance. The 
most common mechanism of acquired resistance is via 
reactivation of the MAPK/ERK pathway, which can 
occur upstream, downstream or at the level of BRAF. 
Mechanisms of acquired resistance include (summary in 
Table 2):
Upstream reactivation of MAPK/ERK
Upstream reactivation is thought to occur via 
upregulation of receptor tyrosine kinases (Figure 1A), 
resulting in continued cellular proliferation via ARAF 
and CRAF kinases, instead of BRAF kinase. BRAFV600E 
melanoma treated with BRAF inhibitors may acquire drug 
resistance through flexible switching between different 
RAF isoforms capable of reactivating the ERK pathway. 
Three main RAF isoforms exist: ARAF, BRAF and 
CRAF [23]. Cancer cells may switch between these RAF 
variants, upregulating ARAF or CRAF when BRAF is 
blocked [34]. One mechanism is ERK negative feedback 
on RAS: Treatment with BRAF inhibitors arrests tumor 
growth by inhibiting the ERK pathway. Blockage of 
this pathway relieves ERK negative feedback on RAS, 
partially restoring RAS activity. RAS activation leads 
to RAS-induced BRAFV600E dimers. BRAF inhibitors 
bind one component of each dimer and transactivate the 
other unbound molecule. This partially reactivates ERK 
signaling and reduces the long-term efficacy of BRAF 
inhibitor therapy [35].
The MAPK/ERK pathway can also be reactivated 
upstream of BRAF by mutations in RAS, meaning 
proliferation can continue, as RAS acts on ARAF and 
CRAF and compensates for the loss of BRAF [36]. These 
pathways could act as alternative survival routes for 
melanoma cells when BRAF signaling has been inhibited 
[37]. Mutated RAS-GTP cannot return to its inactive 
GDP-bound state and becomes constitutively active. 
Mutant RAS-GTP enhances BRAFV600E dimerization, 
reactivates the ERK pathway and confers resistance to 
BRAF inhibitors since these drugs only block monomeric 
BRAFV600E [38]. 
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Table 2: Proposed causes of intrinsic and acquired resistance to BRAF inhibitors
Gene mutation/cause of 
resistance
Proposed mechanisms of resistance
Intrinsic mechanisms
Loss of PTEN PTEN is a crucial suppressor of the PI3K/AKT pathway. Loss of PTEN leads to constitutive 
activation of the pathway and allows cell proliferation to continue even in the presence of BRAF 
inhibition.
RAC1P29S RAC1P29S mutation sustains MAPK signaling even in the presence of BRAF inhibitors, so cell 
proliferation can continue despite inhibition.
Overexpression  
of MAP3K8
MAP3K8 encodes the COT protein. COT can independently activate the MAPK/ERK pathway, 
and so increased levels of COT mean cellular proliferation continues despite BRAF inhibition.
Hepatocyte growth factor 
(HGF) secretion by 
stromal cells
Secretion of HGF by stromal cells leads to activation of MET, a receptor for HGF, reactivate the 
MAPK/ERK and PI3K/AKT pathways, leading to BRAF inhibitor resistance. 
Loss of NF1 tumor 
suppressor gene
NF1 is a negative regulator of RAS signaling. Loss of NF1 by mutation allows RAS increase, 
subsequent CRAF activation, leading to activation of the MAPK pathway, even in the presence 
of BRAF inhibition.
Amplification of CCND1 CCND1 encodes Cyclin D1, a key cell cycle regulator, which can help bypass proliferation 
inhibition by BRAF inhibitors.
Acquired mechanisms
Relief of ERK negative 
feedback
BRAF inhibitor arrest tumor growth by inhibiting the ERK pathway. This relieves ERK negative 
feedback on RAS, partially restoring RAS activity leading to RAS-induced BRAFV600E dimers. 
BRAF inhibitors bind one and transactivate the other BRAF, reducing BRAF inhibitor therapy.
RAS-activating mutations Mutated RAS-GTP becomes constitutively active, enhances BRAFV600Edimerisation, reactivates 
the ERK pathway and confers resistance to BRAF inhibitors which only block monomeric 
BRAFV600E. 
BRAFV600E alternative 
splicing
A BRAFV600E splice variant p61BRAFV600E due to mutations or epigenetic changes could form 
dimers in a RAS-independent manner, making the BRAF inhibitor ineffective as it blocks 
monomeric BRAFV600E.
BRAFV600E 
overexpression
Increased BRAFV600E levels due to gene copy number gain may also promote spontaneous 
BRAFV600E dimerization, reactivating the ERK pathway and causing treatment failure in some 
patients.
Alternative RAF isoforms BRAFV600E melanoma treated with BRAF inhibitors may acquire resistance through flexible 
switching between different RAF isoforms capable of reactivating the ERK pathway, upregulating 
ARAF or CRAF.
COT overexpression COT, possibly due to gene amplification or yet unidentified mechanisms, can reactivate MEK in 
the presence of BRAF inhibition, stimulating ERK signaling and driving resistance. 
MEK-activating 
mutations
Activating mutations in MEK1/ MEK2 render BRAF blockage ineffective, as MEK reactivation 
means the MAPK/ERK pathway can still proceed downstream of BRAF regardless of its 
inhibition.
Adaptive PI3K/AKT 
signaling
Abnormal PI3K/AKT signaling is a common feature of melanomas. Blockage of ERK signaling 
may lead to adaptive PI3K/AKT hyperactivity that compensates for BRAF inhibition and drives 
resistance.
Upregulation of RTKs The PI3K/AKT-pathway is activated by growth factors that bind to RTKs, such as PDGFR-β and 
IGF-1R. With BRAF blockade, tumor cells may upregulate these leading to persistent PI3K/AKT 
signaling.
PI3K/AKT-activating 
mutations
PI3K and AKT-activating mutations enhance AKT-signaling, which increases anti-apoptotic 
signals and upregulates expression of key proliferative genes, allowing survival signals 
independently of BRAF.
Enhanced EGFR 
signaling
Upregulation/activation of EGFR driven by suppression of SOX10 and enhanced TGF-β 
signaling, conferring oncogene-induced senescence, reversed with BRAF/MEK inhibition.
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Downstream reactivation of MAPK/ERK
This is thought to occur mainly through activating 
mutations in mitogen-activated protein kinases, MEK1/ 
MEK2. This may overcome BRAF inhibition, as MEK 
reactivation means that the need for BRAF to stimulate 
production of MEK is removed.
Reactivation of MAPK/ERK at the level of BRAF
Reactivation at the level of BRAF itself can occur 
in several ways, many of which result in amplification 
of the mutant BRAF allele [39]. In many cases, copy 
number amplification means BRAF is overexpressed. 
Consequently, normal doses of BRAF inhibitors cannot 
sufficiently inhibit the increased levels of BRAF. 
Increased BRAFV600E levels due to gene copy number gain 
may also promote spontaneous BRAFV600E dimerization, 
reactivating the ERK pathway and causing treatment 
failure in some patients [39]. This has been described 
as an example of ‘drug-saturable’ resistance since 
administering higher doses of vemurafenib, to cell lines 
in which BRAF was over-expressed, demonstrated that 
the cells were still sensitive to the drug: it was simply 
that the BRAF inhibitor was impeded by the increased 
BRAF levels [39]. Furthermore, a BRAFV600E splice 
variant called p61BRAFV600E was detected in a subset of 
patients with acquired resistance to vemurafenib [40]. The 
variant could form dimers in a RAS-independent manner, 
making the BRAF inhibitor ineffective since it can only 
block monomeric BRAFV600E. Generation of such isoforms 
is probably due to mutations or epigenetic changes that 
affect BRAF splicing [41].
Upregulation of PI3K/AKT
The PI3K/AKT-pathway interacts with several 
components of the ERK-pathway and the inhibition 
of either pathway may upregulate the other. Blockage 
of ERK signaling may lead to adaptive PI3K/AKT 
hyperactivity that compensates for BRAF inhibition and 
drives resistance [42]. Abnormal PI3K/AKT-signaling is 
a common feature of melanomas and causes resistance by 
stimulating alternative pathways that decrease dependence 
on ERK signaling. Mutations leading to upregulation of 
the PI3K/AKT pathway have been identified in 22% of 
melanomas with acquired resistance to BRAF inhibition 
[43]. A study found that within days of administering 
BRAF inhibitors, subsequent increased levels of AKT 
occur [44]. The study hypothesized that there would be 
a strong selective pressure towards cells with gain-of-
function mutations, leading to increased activity of the 
PI3K/AKT pathway, in the presence of MAPK pathway 
inhibition. These cells would proliferate as they would 
have a survival advantage by not being affected by BRAF 
inhibition, and may account for the presence of an even 
greater tumor burden in patients who have responded to 
BRAF inhibition but then develop resistance [44]. The 
PI3K/AKT-pathway is activated by growth factors that 
bind to RTKs, such as PDGFR-β and IGF-1R. When 
BRAF is blocked, tumor cells may increase PDGFR-β 
and IGF-1R expression, leading to persistent PI3K/AKT-
signaling that prevents apoptosis and promotes survival 
[45]. High surface expression of these receptors is 
associated with acquired resistance to vemurafenib both 
in vitro and in vivo [34]. Furthermore, PI3K and AKT-
activating mutations may enhance AKT signaling, which 
increases anti-apoptotic signals and upregulates expression 
of key proliferative genes. These changes allow cancer 
cells to survive and replicate independently of BRAF, 
giving rise to acquired resistance [46].
Enhanced EGFR signaling in low SOX10-expressing 
melanomas
Upregulation and activation of the epidermal 
growth factor receptor (EGFR) may also be associated 
with resistance to BRAF or MEK inhibition. Suppression 
of SOX10 in a proportion of melanomas can lead to 
TGF-β signaling and consequently to EGFR and platelet-
derived growth factor receptor-β (PDGFRB) upregulation, 
conferring oncogene-induced senescence. This is reversed 
with BRAF or MEK inhibition, allowing low-expressing 
SOX10 tumor cells to be enriched in response to treatment 
[47].
Key aims of future research regarding resistance to 
current therapies include: further elucidating mechanisms 
of resistance and determining their relative power in 
reducing treatment efficacy; determining if certain 
mechanisms develop as a result of particular therapies; 
discovery of further shared mechanisms of resistance 
between classes of therapy, which may advise choice of 
further therapy; and identifying biomarkers of the patient’s 
intrinsic resistance state, before initiation of therapy, in 
order to predict response.
EFFORTS TO IMPROVE RESPONSES 
THROUGH THERAPEUTIC COMBINATIONS
Many of the mechanisms by which BRAF resistance 
develops involve alternate ‘survival pathways’, through 
which melanoma cells circumvent the role of BRAF, 
and thus continue to proliferate. Therefore, it has been 
reasoned that by using multiple inhibitors concurrently 
these alternate survival pathways could be simultaneously 
targeted to prevent, or overcome, resistance and improve 
survival. These concepts have resulted in the approval of 
treatment combinations (Table 1), and have given rise to 
several clinical trials (Table 3).
Combination therapies targeting the MAPK/
ERK pathway
Since MEK activation has been identified as an 
important mechanism of BRAF inhibitor resistance, 
a potential synergistic effect of combining BRAF and 
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Table 3: Current phase III trials of combination therapies in melanoma. Information sourced from 
ClinicalTrials.gov.
Combinations of pathway inhibitors
ClinicalTrials.gov 
Identifier
Drug type Treatment combinations Indication and inclusion 
criteria
Status
NCT01584648 BRAF inhibitor + 
MEK inhibitor
Comparing dabrafenib + 
trametinib 
vs.
Dabrafenib monotherapy
Stage IIIC (unresectable) or 
Stage IV BRAF V600E/K-mutant 
melanoma
First line treatment 
Active, not recruiting
NCT01682083 BRAF inhibitor + 
MEK inhibitor
Dabrafenib + trametinib vs. 
placebo
Adjuvant treatment of high risk 
V600E/K mutation-positive 
melanoma after surgical resection
Active, not recruiting
NCT01909453 BRAF inhibitor + 
MEK inhibitor vs. 
BRAF inhibitor alone
LGX818 + MEK162
vs. 
vemurafenib monotherapy 
or 
LGX818 monotherapy
Locally advanced, unresectable 
or metastatic BRAF V600E/K-
mutant melanoma
First line treatment or second 
line in patients who have 
progressed on or after first line 
immunotherapy
Active, not recruiting
NCT01597908 BRAF inhibitor + 
MEK inhibitor vs. 
BRAF inhibitor alone
Dabrafenib + trametenib 
vs. 
vemurafenib monotherapy
Stage IIIC (unresectable) or 
Stage IV BRAF V600E/K-mutant 
melanoma
First line treatment
Active, not recruiting
NCT01689519 BRAF inhibitor + 
MEK inhibitor vs. 
BRAF inhibitor alone
vemurafenib + cobimetinib
vs. 
vemurafenib monotherapy
Stage IIIC (unresectable) or 
Stage IV BRAF V600E/K-mutant 
melanoma
First line treatment
Active, not recruiting
Combination of pathway inhibitors with immunotherapies
ClinicalTrials.gov 
Identifier
Drug type Treatment combinations Indication and inclusion 
criteria
Status
NCT02908672 Anti-PDL1 antibody 
+ MEK inhibitor 
+ BRAF inhibitor 
vs. placebo + MEK 
inhibitor + BRAF 
inhibitor
Atezolizumab + cobimetinib 
+ vemurafenib
vs. 
placebo + cobimetinib + 
vemurafenib
Stage IIIC (unresectable) or 
Stage IV BRAF V600E/K-mutant 
melanoma
First line treatment 
Recruiting
NCT02967692 Anti-PD-1 antibody 
+ BRAF inhibitor + 
MEK inhibitor vs. 
placebo + BRAF 
inhibitor + MEK 
inhibitor
PDR001 + dabrafenib + 
trametinib 
vs. 
placebo + dabrafenib + 
trametinib
Stage IIIC (unresectable) or 
Stage IV BRAF V600E/K-mutant 
melanoma
First line treatment 
Recruiting
Combinations of immunotherapies
ClinicalTrials.gov 
Identifier
Drug type Treatment combinations Indication and inclusion 
criteria
Status
NCT02599402 Anti-PD-1 antibody 
+ anti-CTLA-4 
antibody followed 
by anti-PD-1 
monotherapy
Nivolumab + ipilimumab 
followed by 
nivolumab monotherapy
Stage IIIC (unresectable) or Stage 
IV melanoma
First line treatment 
Recruiting
NCT02714218 Anti-PD-1 antibody+ 
anti-CTLA-4 
antibody
Two different dose 
combinations of nivolumab + 
ipilimumab
Stage III (unresectable) or Stage 
IV melanoma
First line treatment 
Active, not recruiting
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MEK inhibitors has been sought. The combination 
of dabrafenib and trametinib has been evaluated in 
phase III trials [48, 49]. In one trial (COMBI-d), 
patients were randomised to either dabrafenib and 
placebo or dabrafenib and trametinib. The ORR 
was 54% vs. 76% and the median PFS 8.8 months 
(95% CI 5.9–9.3) vs. 11.0 (95% CI 8·0–13·9) 
months (HR 0·67, 95% CI 0·53–0·84; p = 0.0004) 
with monotherapy vs. combination treatment [48]. 
In another trial, dabrafenib and trametinib were 
compared to vemurafenib alone, showing ORR of 
64% vs. 51% (P < 0.001) and median PFS 11.4 
months vs. 7.3 months (HR 0.56; 95% CI, 0.46–0.69; 
P < 0.001) [49]. The merits of combination therapies 
were also supported by findings from the coBRIM 
study, that compared vemurafenib combined with 
the MEK inhibitor cobimetinib vs. vemurafenib 
alone in previously untreated unresectable BRAF-
mutant melanoma. Combination therapy demonstrated 
superior efficacy to monotherapy as the ORR and PFS 
were again significantly higher in the combination 
arm:  ORR for combination therapy was 68% compared 
with 45% in the control group (P < 0.001); median PFS 
was 9.9 months in the combination group vs. 6.2 months 
in the control group (HR 0.51; 95% CI 0.39–0.68; P < 
0.001) [50]. Administering combinations of BRAF and 
MEK inhibitor drugs may thus slow the development 
of resistance, as tumors cannot use the alternate MEK 
survival pathway to proliferate. 
Furthermore, the recent development of potent 
highly selective BRAF and MEK inhibitors with unique 
pharmacologic profiles, has led to the potential for 
improved survival of patients with locally advanced 
or metastatic melanoma. The COLOMBUS trial 
compared the combination of the selective BRAF 
inhibitor encorafenib and the selective MEK inhibitor 
binimetinib versus treatment with vemurafenib or 
encorafenib alone. A median PFS of 14.9 months for 
the combination therapy compared to 7.3 months for 
vemurafenib (HR 0.54; 95% CI 0.41–0.71; P < 0.001) 
was reported in patients with BRAF mutant melanoma, 
with a favorable safety profile for the combination [51]. 
While the combination of encorafenib and binimetinib 
did not significantly improve survival compared with 
encorafenib alone (14.9 months vs. 9.6 months, HR 
0.75; 95% CI 0.56–1.00, P = 0.051), these results 
still emphasize the potential benefit of using highly-
selective BRAF and MEK inhibitors alone or in 
combination [51].
Another study however, found that administration 
of BRAF inhibitors not only led to acquired resistance to 
BRAF inhibitors, but also conferred resistance to MEK 
inhibitors, suggesting that combination therapy slows 
down but does not prevent the development of resistance 
[52]. It is worth noting that this study was carried out 
on cell lines, rather than in vivo, however the findings 
identified that BRAF-resistant cell clones were less 
sensitive to MEK inhibition as well as combined BRAF/
MEK inhibition compared with parental cells, suggesting 
shared mechanisms of resistance [52]. This may suggest 
that additional inhibition of different signaling pathways 
outside of MAPK/ERK, may better overcome BRAF 
resistance (Figure 1A). 
Recently, the potential of intermittent dosing 
schedules of BRAF and MEK inhibitors to extend disease 
control in BRAF mutant melanoma has been explored. 
In an in vivo xenograft model of melanoma, intermittent 
dosing of vemurafenib was shown to delay the onset of 
drug resistance compared to continuous dosing. The 
authors suggested that intermittent dosing significantly 
delayed the onset of drug resistance by exploiting the 
‘fitness deficit’ shown by drug-resistant tumour cells in 
the absence of drug, potentially by reversing epigenetic 
mechanisms [53]. In concordance, a recent clinical 
case report described ongoing complete remission in 
a patient treated with an intermittent dosing regimen 
NCT02460068 Alkylating agent vs. 
alkylating agent+ anti-
CTLA-4 antibody vs. anti-
CTLA-4 antibody +anti-
PD-1 antibody
Fotemustine monotherapy 
vs. 
fotemustine + ipilimumab 
vs. 
ipilimumab + nivolumab
Stage IV melanoma with brain 
metastases
First line treatment 
Recruiting
NCT03068455 Anti-PD-1 antibody + 
anti-CTLA-4 antibody vs. 
anti-PD-1 antibody or anti-
CTLA-4 antibody alone
Nivolumab + ipilimumab 
vs. 
nivolumab monotherapy 
or 
ipilimumab monotherapy
Completely surgically resected stage 
IIIB/C/D or stage IV melanoma
Adjuvant treatment
Recruiting
NCT01844505 Anti-PD-1 antibody vs. 
anti-PD-1 antibody+ anti-
CTLA-4 antibody vs. anti-
CTLA-4 monotherapy
Nivolumab monotherapy 
vs. 
nivolumab + ipilimumab
vs. 
ipilimumab monotherapy
Stage III (unresectable) or Stage IV 
melanoma
First line treatment 
Active, not 
recruiting
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of vemurafenib followed by cessation of vemurafenib 
therapy [54]. Similarly, a recent retrospective study 
which examined re-challenging patients previously 
treated with a BRAF inhibitor, with a BRAF +/− MEK 
inhibitor following subsequent treatment or a treatment 
break, demonstrated clinically significant responses to 
re-challenge [55]. Intermittent dosing of BRAF/MEK 
inhibitor combinations has also been suggested to delay 
the emergence of resistance in BRAF mutant melanoma, 
and this is currently being investigated in a randomized 
phase 2 clinical trial of continuous versus intermittent 
dosing of dabrafenib with trametinib [56].
While beyond the scope of this review, it is 
noteworthy that ERK inhibitors including ulixertinib 
have undergone promising phase I trials in patients with 
V600E-positive and negative melanoma, pointing an 
additional future treatment avenue [57]. 
Combining immunotherapy and BRAF 
inhibition
The promise of immunotherapy for melanoma
Immunotherapy involves utilizing the body’s 
immune system to target cancer cells. The emergence 
of immunotherapies, especially checkpoint inhibitor 
antibodies, has provided the impetus for considering these 
in combination therapies with pathway inhibitors (Table 3).
CTLA-4 (Cytotoxic T-lymphocyte-associated protein 
4) is a checkpoint molecule expressed on the surface of T 
cells that is involved in the suppression of T cell activity 
through competing with the co-stimulatory CD28 molecule 
for binding to CD80 and CD86, on the surface of antigen-
presenting cells [58]. The monoclonal antibody ipilimumab 
is designed to target CTLA-4 and interfere with its T cell 
blocking functions, thus increasing the activation state 
and responsiveness of T cells. Ipilimumab was licensed 
by the Food and Drug Administration (FDA) for the 
treatment of malignant melanoma in 2011. This approval 
followed a successful phase III trial in which ipilimumab 
improved overall survival in unresectable stage III or IV 
disease in patients who had progressed on prior therapy 
[59]. Patients were randomized to ipilimumab, ipilimumab 
plus glycoprotein 100 peptide vaccine (gp100), or gp100 
alone. Median overall survival in the ipilimumab and gp100 
combination group was 10.0 months (95% CI, 8.5–11.5), 
in the ipilimumab alone group was 10.1 months (95% CI, 
8.0–13.8) as compared with 6.4 months (95% CI, 5.5–8.7) 
in the gp100-alone group (HR 0.68; P < 0.001 and 0.66; P 
= 0.003 respectively) [59]. This study identified ipilimumab 
as the first agent to show a survival benefit in melanoma 
for decades.
Similarly, another checkpoint molecule, the 
programmed cell death protein 1 (PD-1), is expressed 
by B and T cells, and is upregulated by antigen-educated 
lymphocytes as a means of switching off cell activation 
and limiting normal tissue damage [60]. Melanoma cells 
express the PD-1 ligand (PD-L1), which can recognize 
PD-1 on T cells and can suppress T cell activity. 
Pembrolizumab and nivolumab are anti-PD-1 antibodies 
thought to act by preventing PD-L1 engagement of 
PD-1 on the surface of T cells, thereby preventing T 
cell anergy or deletion. In late stage clinical trials, these 
agents showed ORR of 30–40% and were approved as 
monotherapies by the FDA and the European Medicines 
Agency (EMA) in 2014. 
In a pivotal phase III trial, pembrolizumab (10 mg/kg) 
every 2 or 3 weeks or ipilimumab  (4 doses at 3 mg/kg) 
every 3 weeks [61]. ORR were 33.7% for pembrolizumab 
every 2 weeks and 32.9% for pembrolizumab every 3 
weeks compared with 11.9% for ipilimumab. After a 
7.9-month median follow up, ongoing responses were 
recorded at 89.4% for pembrolizumab every 2 weeks, 
96.7% for pembrolizumab every 3 weeks, and 87.9% for 
ipilimumab. The 12-month survival rates were 74.1%, 
68.4% and 58.2%, respectively (pembrolizumab every 
2 weeks, HR 0.63; 95% CI, 0.47–0.83; P < 0.0005, 
and pembrolizumab every 3 weeks, HR 0.69; 95% CI, 
0.52–0.90; P = 0.0036) each compared with ipilumumab 
[61]. These findings led to the regulatory approval 
for pembrolizumab (dosed every three weeks) for the 
treatment of melanoma by the FDA and the EMA. 
In the Checkmate 067 phase III study, nivolumab 
plus ipilimumab combination treatment was compared 
with nivolumab or ipilimumab monotherapies in patients 
with metastatic melanoma. Nivolumab and ipilimumab 
combination treatment resulted in PFS of 11.5 months (HR 
0.42, 99.5% CI, 0.31–0.57; P < 0.001); 6.9 months for 
nivolumab (95% CI, 4.3–9.5) (HR 0.57; 99.5% CI, 0.43–
0.76; P < 0.001) and 2.9 months or ipilimumab (95% CI, 
2.8–3.4) [62]. Nivolumab plus ipilimumab combination 
treatment was approved by the FDA in 2015. A recent 
update on CheckMate 067 showed a superior ORR for 
ipilmumab plus nivolumab of 58.9 months (95% CI 53.3–
64.4) compared to 44.6 (95% CI 39.1–50.3) for nivolumab 
and 19.0 months (14.9–23.8) for ipilimumab [63]. Notably 
the emergence of immune-related adverse events (irAEs) 
with the checkpoint inhibitors vary in frequency and 
intensity depending on the target and regimen used [64]. 
The CTLA-4-targeting antibodies confer greater toxicity 
than antibodies targeting the PD-1/PD-L1 axis. Combining 
CTLA-4 and PD-1 therapy leads to a sharp rise in the risk 
of severe toxicity (requiring hospitalization in over a third 
of patients treated on the Checkmate 067 protocol) [62].
Since only a proportion of patients benefit from 
checkpoint inhibitor therapy, and in light of often 
significant adverse events observed in the clinic, there 
remains a need for standardized patient stratification in 
order to determine which patients are likely to benefit. An 
example of patient stratification is seen in non-small cell 
lung cancer (NSCLC), where PD-L1 tumor status is used 
as a biomarker of potential response to pembrolizumab 
therapy [65]. Despite benefits to be had from identifying 
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patients who will respond to anti-PD-L1 antibodies, PD-
L1 status is not completely reliable for stratification in 
melanoma. Chemotherapy has been suggested to alter 
PD-L1 expression levels so that status may change 
following therapy, and a standardized cut-off point for 
what constitutes a ‘PD-L1 negative’ tumor has not yet 
been established [66]. More research is therefore required 
so that reliable biomarker testing can be implemented, to 
improve selection for checkpoint inhibitor treatment for 
patients with melanoma.
Molecular and immunological resistance to 
immunotherapy
Despite encouraging results, as with BRAF/MEK 
inhibitors, immunotherapy too encounters problems in 
the form of resistance. The mechanisms of resistance to 
immunotherapy continue to form the subject of intense 
study. Of interest, the effect of copy number loss of tumor 
suppressor genes, such as PTEN has been implicated 
in disease progression (Figure 1B). In 2017, a study 
of integrated molecular analysis of tumor biopsies, 
demonstrated that high burden of copy number loss was 
associated with disease progression despite sequential 
CTLA-4 blockade, and PD-1 blockade, compared with 
those biopsies from patients who responded to CTLA-
4 blockade [67]. The authors also demonstrated that T 
cell receptor (TCR) clonality positively correlated with 
both treatment response and with pre-treatment immune 
scores (used to estimate immune activation, within the 
tumor microenvironment), with regards to PD-1, but not 
to CTLA-4, blockade [67]. Loss of PTEN on chromosome 
10 increased the odds of resistance 5.58-fold, compared 
with patient tumors with no PTEN loss [67].
Studies also point to tumor-associated macrophages 
as potential decoy cells by sequestering anti-PD-1 
antibodies away from their T cell targets through Fc 
gamma receptor engagement [68]. Such mechanisms 
suggest that perhaps reducing the macrophage and 
immunomodulatory cell infiltrate in tumors by pathway 
blocking agents may be beneficial prior to or alongside 
checkpoint therapy. Alternatively, novel antibody 
engineering approaches including enhancing target 
engagement and improving antibody activatory effector 
functions or strategies that might be able to activate tumor-
associated macrophages and other effector cells against 
tumors may help overcome resistance [69].
Rationale and clinical study of pathway inhibitor 
combinations with immunotherapy
While checkpoint blocking antibodies have been 
independently effective at increasing survival of subsets 
of patients with melanoma, combining immunotherapies 
with BRAF and MEK inhibitors is an enticing prospect. 
Identifying the right combination of immunotherapy 
and BRAF and/or MEK inhibition may confer improved 
and more sustained responses, even in the face of BRAF 
inhibitor resistance [70]. 
From a clinical viewpoint, MAPK pathway 
inhibitors induce a relatively short-lived tumor response 
in most patients with BRAF-mutated melanoma. 
Furthermore, most patients still do not gain long term 
benefit from checkpoint inhibitors. For those patients 
who respond, disease control can be maintained for many 
years. Therefore, it is plausible that pathway inhibitor/
immunotherapy combinations may induce maintained 
responses in a greater proportion of patients. 
From a biological perspective, it is hypothesized 
that MAPK pathway inhibitors may potentiate an anti-
tumor immune response, which could then be enhanced 
through immune checkpoint inhibition. Additionally, 
destruction of cancer cells by MAPK pathway inhibitors 
could reduce the immunosuppressive effects conferred by 
tumor environments. This may allow immunotherapeutic 
agents to act more effectively in favor of T cell activation 
and survival of tumor antigen-specific T cell clones. 
Studies from pre-clinical models of melanoma and those 
from patients treated with vemurafenib and dabrafenib 
report evidence of enhanced infiltrating T cell levels, 
reduced CD11b+/Gr-1+ MDSC and reduced FoxP3+ Treg 
frequencies in tumors [71]. These studies may suggest 
that immunological activation may associate with and 
complement responses to MAPK pathway inhibitors [72].
Furthermore, tumor cell death effected by pathway 
inhibitors may also lead to increased tumor antigens 
available for uptake by antigen-presenting cells and 
presentation to cognate T cells [73]. When combined with 
T cell-activating immunotherapies, BRAF inhibitors, and 
possibly combinations of BRAF and MEK inhibitors, 
may augment adaptive immune responses against cancer 
cells. This notion is supported by pre-clinical findings that 
BRAF inhibitor therapy can enhance IFNγ production, T 
cell proliferation and MHC expression by melanoma cells, 
and by clinical evidence of increased tumor-infiltrating 
lymphocyte populations during BRAF inhibitor therapy 
[71, 74–75]. In further support, BRAFV600E inhibitor 
treatments have been associated with dendritic cell 
maturation, increased expression of co-stimulatory 
molecules including CD40L, production of IFNγ, TNFα 
and IL-12, and moderate enhancement of circulating tumor 
antigen-reactive CD8+ T cells [76, 77–78]. Pre-clinical 
evidence of combinations of BRAF inhibition, MEK 
inhibition and anti-PD-1 antibody treatment also suggest 
superior anti-tumor effects compared with monotherapy 
[79]. This was corroborated by experimental findings 
of enhanced effects with BRAF and MEK inhibitor 
combinations together with either adoptive cell transfer or 
with anti-PD-1 therapy, associated with heightened 
immune marker expression, MHC upregulation and T 
cell infiltration [80, 81]. Immunological mechanisms may 
also be responsible for early reports of clinical benefits 
from combination therapy with the anti-PD-L1 antibody 
atezolizumab and the MEK inhibitor cobimetinib in 
patients with BRAFV600E mutant and BRAF wild-type 
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melanoma. It has been postulated that the pathway 
inhibitor may sensitize tumors by supporting enhanced 
MHC Class I expression and infiltration of cytotoxic 
T cells A planned phase III trial will compare the 
combination of a PD-L1 inhibitor with a MEK inhibitor 
versus a PD-L1 inhibitor alone.  
In the same way that melanoma has been postulated 
to share resistance mechanisms to both BRAF and MEK 
inhibitors, a major limitation to the success of future 
combination therapies, could be conferred resistance to 
BRAF/MEK inhibitors and immunotherapy. As previously 
mentioned, PTEN loss has been strongly implicated as a 
mechanism to intrinsic BRAF resistance. Hence loss of 
this tumor suppressor gene, via mutations, methylation 
or high copy number loss, may represent a shared 
mechanism of resistance between BRAF inhibitors and 
immunotherapy (Figure 1B). 
There are currently a few clinical trials underway 
aimed at assessing potential clinical applications of 
different pathway inhibitor treatment combinations with 
immunotherapies (Table 3). However, results to-date 
suggest that combination therapy may be hampered 
by significant toxicities such as hepatotoxicity and 
bowel perforation, and this may undermine efficacy 
in the long term [82, 83]. Data from a phase I study of 
the combination of BRAF/MEK inhibition and an anti-
PD-1 antibody demonstrated increased levels of tumor-
infiltrating T cells even post-treatment, a potential 
indication of increased immune activation [84]. However, 
ongoing overall response rates to this triple therapy do not 
appear to be better than the response rate to BRAF and 
MEK inhibition dual therapy [85]. Further understanding 
of the mechanisms of resistance to BRAF/MEK 
inhibitors and immunotherapy is required to determine 
if conferred resistance between all of these classes, could 
be responsible for current response rates. Nevertheless, 
further studies, examining dual treatment combinations 
of MAPK pathway and immune checkpoint inhibitors, 
provide hope that some combined treatment regimens may 
be better tolerated [86].
SEQUENCING OF THERAPY, GENOMIC 
CORRELATES AND THE POTENTIAL OF 
PATIENT STRATIFICATION
There has been a relatively quick transition from 
having few therapeutic options for the treatment of 
melanoma before 2011, to FDA and EMA approval 
of pathway inhibitors and of checkpoint blocking 
antibodies. To-date, the EMA and the FDA have approved 
vemurafenib, dabrafenib, and trametinib as monotherapies, 
combined dabrafenib and trametinib, and combination of 
vemurafenib and cobimetinib; ipilimumab, nivolumab, 
pembrolizumab and T-Vec monotherapies, and combined 
ipilimumab and nivolumab (Table 1). The next challenge 
is to discern the optimum order in which to administer 
agents, in order to gain the maximum clinical benefits for 
melanoma patients.
It has been postulated that the right sequence of 
treatment may hold the key to improving responses 
and survival [87]. For instance, first line BRAF/
MEK inhibition followed by an immune checkpoint 
inhibitor, may allow a quick initial response to treatment 
and the ability to prime the immune system before 
administering immunotherapy. On the other hand, first 
line immunotherapy may provide an opportunity to benefit 
patients by triggering immunological memory and the 
possibility of discontinuing treatment whilst maintaining 
a response – not an option with BRAF inhibition. It is 
hoped that future trials will ascertain an optimal treatment 
pathway.
Mechanisms of immune evasion in melanoma are 
plentiful. Mutant BRAF not only promotes melanocyte 
proliferation but has also been shown to manipulate the 
tumor microenvironment by increasing the release of IL-
6, IL-10 and VEGF [73]. By increasing levels of these 
immunosuppressive mediators and recruiting regulatory 
T cells BRAF mutations may promote immune tolerance, 
conferring a survival advantage to malignant cells [73]. On 
the other hand, recognition of mutant BRAF can induce an 
immune response. Synthetic BRAFV600E has been shown 
to generate peptide-specific MHC class II-restricted 
CD4+ T cells, in vitro [88]. Another in vitro study 
demonstrated cytotoxic T cell activity, against melanoma 
cells with BRAFV600E and HLA-A2 binding sites [89]. 
Whilst the mechanisms by which mutant BRAF induces 
immunogenicity are eclipsed by its varied instruments of 
immune evasion, V600E mutations could provide a known 
therapeutic target. 
A 2015 study using next generation sequencing 
in 10 patients with BRAFV600E found that 2 out of 3 
patients, with long term complete response, had no other 
mutation in BRAF or other genes [90] However, the third 
patient not only had another BRAF mutation (T5995), 
but an aurora kinase a amplification [90]. The relative 
importance of non-V600E mutations (including other 
BRAF mutations and those in other genes) in predicting 
disease progression, response to and possible mechanisms 
of resistance to therapeutic interventions, is unknown. 
Mutational load, neoantigen load and cytolytic 
activity within the immune microenvironment correlate 
significantly with clinical benefit in patients with metastatic 
disease receiving ipilimumab [91]. However, no specific 
sequences of recurrent neoantigens were found consistently 
in those with response to treatment [91]. This is supported 
by a 2016 study, which used an algorithmically-predicted 
mutational load, based on mutational status from cancer 
related genes in melanoma and lung cancer [92]. Predicted 
total mutational load (PTML) correlated with actual total 
mutational load as validated by whole exome sequencing 
datasets. PTML also positively correlated with clinical 
benefit and overall survival in melanoma patients 
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receiving ipilimumab [92]. Another 2016 study examined 
the relationship of mutational load to PD-1 inhibitors in 
metastatic melanoma [93]. Mutational load was found 
to positively correlate with improved survival but, once 
again, no predictive recurrent neoantigens associated with 
response to PD-1 inhibitors were identified [93]. In further 
Figure 1: Influence of pathway resistance mechanisms on BRAF/MEK inhibitor monotherapies and combinations with 
immunotherapies. (A) MAPK signaling inhibition may either result in the survival of tumor cells with activated pathways such as the 
PI3K/AKT, or exert strong selective pressure on melanoma tumors to acquire gain-of-function mutations, methylation or high copy number 
loss of tumor suppressor genes such as PTEN. These can lead to increased activity of alternative pathways (e.g. PI3K/AKT), which could 
confer survival advantages for BRAF/MEK inhibitor-resistant melanomas. (B) The success of combinations of BRAF/MEK inhibitors 
with immunotherapies may also depend on activation of alternative pathways to MAPK. MAPK pathway inhibitors may potentiate an 
anti-tumor immune response by destroying cancer cells and the tumor microenvironment, reducing tumor-associated immunosuppressive 
effects, enhancing IFNγ production, T cell proliferation and MHC expression, all of which could result in tumor antigen presentation 
and more effective anti-tumor immune responses. All or some of these could then be further enhanced with T cell activation and Treg 
destruction, engendered by immune checkpoint inhibition combination or subsequent treatment (top). However, in tumors with mutations 
on pathway genes, including those with loss of PTEN, that support alternative activation of pathways such as the PI3K/AKT, both BRAF/
MEK and checkpoint blockade inhibition as monotherapies or combinations would suffer from resistance. This may be due to impaired T 
cell infiltration into tumors, reduced T cell activation and expansion and loss of immuno-activatory signals (e.g. reduced IFNγ, granzyme 
B release). These may point to shared mechanisms of resistance for BRAF inhibitors and immunotherapies and could partly explain non-
responders to combinatory or sequential BRAF/MEK inhibitor and immunotherapy treatments. 
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support of this, a previously mentioned 2017 study which 
found association between high burden of copy number 
loss and disease progression also analyzed the effect of 
mutational load [67]. Clinical benefit was associated with 
raised mutational load and lower copy number loss, the 
effects of which were found to be non-redundant [67]. 
Whilst mutational load was not found to differ between 
pre-treatment samples of responders or non-responders to 
either checkpoint inhibitor the authors postulated that this 
might be due to sample size [67].
Whilst mutational load has been shown to correlate 
with survival and response to treatment, patients with high 
mutational loads do not always respond to checkpoint 
inhibitors and some patients with low mutational loads 
have been shown to respond [93]. Therefore, at present, 
accurate prediction of survival and response cannot be 
made with mutational load alone. 
Alternatively, the analysis of circulating cell-free 
tumor DNA (cfDNA) may provide a useful approach 
to assess prognosis, monitor therapeutic response 
and detect the onset of resistance [94]. In BRAFV600E 
mutant melanoma, lower levels of BRAFV600E cfDNA 
were associated with a higher ORR and increased 
PFS in patients treated with BRAF inhibitors [95]. 
Furthermore, cfDNA levels correlated with clinical and 
radiological outcomes in a group of patients receiving 
checkpoint inhibitor immunotherapy [96]. Gray et al. 
showed that plasma cfDNA reflected response to BRAF/
MEK inhibitor treatment and could be used to predict 
the onset of acquired resistance in a subset of patients 
[94]. Following treatment initiation, plasma cfDNA 
concentrations declined to almost undetectable levels. 
Subsequently, cfDNA was elevated again in all cases 
of acquired resistance. In some patients, the increase in 
plasma cfDNA preceded detection of progressive disease 
by CT scans. Moreover, NRAS mutations conferring 
resistance to BRAF/MEK inhibitors were identified in 
the cfDNA of patients prior to radiological evidence 
of progression. Thus, circulating cfDNA could provide 
valuable prognostic information and may be used to 
track patient response and tumor evolution. Importantly, 
cfDNA analysis may help predict early resistance and 
allow switching to other more effective therapies [90]. 
Future studies in larger cohorts are needed to confirm the 
predictive value of cfDNA in melanoma. 
Together, these observations mandate further 
dissection of the pathways involved in BRAF resistance. 
Defining reliable predicative markers of prolonged 
efficacy and intrinsic and acquired resistance to targeted 
therapy will enable accurate patient stratification and 
allow the implementation of highly personalized regimens. 
CONCLUSIONS
While resistance to BRAF inhibitors has limited 
their clinical benefits, the emergence of MEK and other 
pathway blockade drugs alongside a new generation 
of immuno-oncology agents, such as the checkpoint 
blocking anti-CTLA-4 and anti-PD-1 antibodies, have 
brought about the possibility of a range of treatment 
combinations. This prospect has raised hopes that better 
responses and prolonged survival for patients could be 
achieved. With some dual agent combinations already 
approved, promising pre-clinical findings of synergistic 
effects with triple or other combination treatments are yet 
to be translated into viable clinical treatments. 
New insights may arise from the clinical experience 
gained with BRAF inhibitors. Activation of pathways 
such as the PI3K-Akt-mTOR could point to new targets 
and selection of treatment combinations that may help 
prevent or overcome resistance. The PI3K inhibitor 
buparlisinib was recently identified as being beneficial in 
melanoma brain metastases [97]. Other mechanisms such 
as those triggered by metabolic pathway alterations may 
also contribute to constitutive activation and, possibly, 
resistance [98]. The nature of immune responses before 
and during treatment and with the onset of resistance 
to pathway inhibitor drugs or combinations may also 
be of critical importance for selection of combinations 
with checkpoint blockade antibodies and with future 
immunotherapies [99, 100].
Also of the utmost importance to both patient 
comfort and safety would be to discover if certain 
combination therapies have different side effect profiles or 
predispose to serious adverse events. Combining multiple 
agents may narrow therapeutic windows, reducing quality 
of life. Benefit and safety results from current phase III 
triple therapy trials will need to be clearly beneficial for 
universal adoption.  
With the treatment landscape of malignant 
melanoma now facing the real prospect of multi-drug 
combinations, numerous challenges remain. These include 
incomplete understanding of resistance mechanisms to 
these new therapies and their combinations, and lack of 
reliable biomarkers to select patients likely to benefit. The 
ultimate goal for the Multidisciplinary Team (MDT) is to 
be able to further personalize care, by offering tailored 
therapy, taking account of co-morbidities, genetics, 
treatment efficacy and understanding their patient’s wishes 
and values. Alongside clinical testing and implementation, 
intense focus on dissecting mechanisms and biomarkers 
of treatment response may hold the key to these novel 
approaches.
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